These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38129390)

  • 1. mRNA-based VP8* nanoparticle vaccines against rotavirus are highly immunogenic in rodents.
    Roier S; Mangala Prasad V; McNeal MM; Lee KK; Petsch B; Rauch S
    NPJ Vaccines; 2023 Dec; 8(1):190. PubMed ID: 38129390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mRNA-Based Vaccines Are Highly Immunogenic and Confer Protection in the Gnotobiotic Pig Model of Human Rotavirus Diarrhea.
    Hensley C; Roier S; Zhou P; Schnur S; Nyblade C; Parreno V; Frazier A; Frazier M; Kiley K; O'Brien S; Liang Y; Mayer BT; Wu R; Mahoney C; McNeal MM; Petsch B; Rauch S; Yuan L
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tandem truncated rotavirus VP8* subunit protein with T cell epitope as non-replicating parenteral vaccine is highly immunogenic.
    Wen X; Cao D; Jones RW; Hoshino Y; Yuan L
    Hum Vaccin Immunother; 2015; 11(10):2483-9. PubMed ID: 26091081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Nanoparticle-Based Trivalent Vaccine Targeting the Glycan Binding VP8* Domains of Rotaviruses.
    Xia M; Huang P; Jiang X; Tan M
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33419150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pseudovirus Nanoparticle-Based Trivalent Rotavirus Vaccine Candidate Elicits High and Cross P Type Immune Response.
    Xia M; Huang P; Tan M
    Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens.
    Agarwal S; Hickey JM; Sahni N; Toth RT; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):380-393. PubMed ID: 31400347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rotavirus NSP4 protein on the immune response and protection of the S
    Liu C; Huang P; Zhao D; Xia M; Zhong W; Jiang X; Tan M
    Vaccine; 2021 Jan; 39(2):263-271. PubMed ID: 33309483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of P[8], P[4], and P[6] VP8* genes of human rotaviruses globally reported during 1974 and 2017: possible implications for rotavirus vaccines in development.
    Velasquez DE; Jiang B
    Hum Vaccin Immunother; 2019; 15(12):3003-3008. PubMed ID: 31124743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma VP8∗-Binding Antibodies in Rotavirus Infection and Oral Vaccination in Young Bangladeshi Children.
    Lee B; Colgate ER; Carmolli M; Dickson DM; Gullickson S; Diehl SA; Ara R; Alam M; Kibria G; Abdul Kader M; Afreen S; Ferdous T; Haque R; Kirkpatrick BD
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):127-133. PubMed ID: 34904667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice.
    Xia M; Huang P; Jiang X; Tan M
    Vaccine; 2019 Jul; 37(30):4103-4110. PubMed ID: 31201052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation and preclinical studies with a trivalent rotavirus P2-VP8 subunit vaccine.
    Lakatos K; McAdams D; White JA; Chen D
    Hum Vaccin Immunother; 2020 Aug; 16(8):1957-1968. PubMed ID: 31995444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus ΔVP8* subunit parenteral vaccines.
    Wen X; Wen K; Cao D; Li G; Jones RW; Li J; Szu S; Hoshino Y; Yuan L
    Vaccine; 2014 Jul; 32(35):4420-4427. PubMed ID: 24962749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Viral Protein 4-Based Trivalent Nanoparticle Vaccine Elicited High and Broad Immune Responses and Protective Immunity against the Predominant Rotaviruses.
    Xia M; Huang P; Vago F; Kawagishi T; Ding S; Greenberg HB; Jiang W; Tan M
    ACS Nano; 2024 Feb; 18(8):6673-6689. PubMed ID: 38353701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Immunogenicity of a Monovalent Parenteral P2-VP8 Subunit Rotavirus Vaccine and Fecal Shedding of Rotavirus following Rotarix Challenge during a Randomized, Double-Blind, Placebo-Controlled Trial.
    Fellows T; Page N; Fix A; Flores J; Cryz S; McNeal M; Iturriza-Gomara M; Groome MJ
    Viruses; 2023 Aug; 15(9):. PubMed ID: 37766217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant.
    McAdams D; Lakatos K; Estrada M; Chen D; Plikaytis B; Sitrin R; White JA
    J Immunol Methods; 2021 Jul; 494():113056. PubMed ID: 33857473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.
    Fix AD; Harro C; McNeal M; Dally L; Flores J; Robertson G; Boslego JW; Cryz S
    Vaccine; 2015 Jul; 33(31):3766-72. PubMed ID: 26065919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parenterally Administered P24-VP8* Nanoparticle Vaccine Conferred Strong Protection against Rotavirus Diarrhea and Virus Shedding in Gnotobiotic Pigs.
    Ramesh A; Mao J; Lei S; Twitchell E; Shiraz A; Jiang X; Tan M; Yuan AL
    Vaccines (Basel); 2019 Nov; 7(4):. PubMed ID: 31698824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of porcine P[6], P[7]-specific △VP8* rotavirus subunit vaccines with a tetanus toxoid universal T cell epitope.
    Wen X; Wei X; Ran X; Ni H; Cao S; Zhang Y
    Vaccine; 2015 Aug; 33(36):4533-9. PubMed ID: 26192360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.